EVOGENE LTD. - EVGN STOCK NEWS

Evogene Ltd. (NASDAQ: EVGN) has announced it will release its third-quarter 2022 financial results on November 17, 2022. A conference call is scheduled for 9:00 AM ET the same day. The call will discuss the financial results and can be accessed via phone or live webcast on the company's website. Evogene focuses on developing life-science products through its advanced technological engines, including MicroBoost AI, ChemPass AI, and GeneRator AI. The company aims to enhance product development efficiency while decreasing costs.

Lavie Bio Ltd., a subsidiary of Evogene (Nasdaq: EVGN), has submitted a registration package for its novel bio-fungicide, LAV.311, to the U.S. EPA. This product targets damaging fungal diseases like fruit rots and powdery mildews, addressing a $2 billion market in the U.S. alone. After over 30 successful field trials in various regions, LAV.311 is set for commercial launch in 2024. It promises a sustainable solution amidst declining availability of traditional fungicides, aligning with modern Integrated Pest Management practices.

Evogene Ltd. (Nasdaq: EVGN) announced that President and CEO Ofer Haviv will present at the LD Micro Main Event in Los Angeles from October 25-26, 2022. Mr. Haviv's presentation is scheduled for 10 am PT on October 25, focusing on Evogene's AI-driven technologies and their application in product development. Investors can arrange 1-1 meetings with him at the event. Evogene aims to accelerate life-science product development through its innovative AI engines, including MicroBoost AI, ChemPass AI, and GeneRator AI, each targeting unique market segments.

Canonic Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN), has announced the launch of its second-generation medical cannabis products in Israel. Building on market feedback from its first-generation products released in September 2021, these new products will debut in early October 2022. They feature high THC levels and unique terpene profiles, designed through advanced breeding programs using Evogene's GeneRator AI tech. CEO Arnon Heyman highlighted the improvements in cannabinoid and terpene concentrations to meet patient needs.

Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN), has appointed Guri Oron as its new Chief Executive Officer, effective September 18, 2022. Oron, a seasoned executive with over 20 years of experience in ag-tech, has previously led companies including Viridix Ltd. and BlueWind Medical Ltd. His leadership aims to enhance Lavie Bio's mission to improve food quality and sustainability through microbiome-based products. The company is expected to scale its bio-stimulant manufacturing and continue partnerships with Corteva and ICL Group.

Canonic Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN), has signed a licensing agreement with GroVida in Portugal for the cultivation and commercialization of its cannabis varieties. This marks Canonic's first entry into the European market, which has a projected medical cannabis sales figure of €400 million for 2021. GroVida will pay royalties based on sales and aims to enhance product offerings throughout the EU and UK. Canonic plans to initiate direct sales in Germany, leveraging its AI-driven cannabis variety development.

Evogene Ltd. (Nasdaq: EVGN) announced that Ofer Haviv, President and CEO, will present virtually at the H.C. Wainwright 24th Annual Global Investment Hybrid Conference from September 12-14, 2022. The presentation will highlight Evogene's innovative AI engines for biological product development and its ecosystem of subsidiaries and partnerships. The presentation will be available on the conference website starting at 7am ET on September 12. Additionally, Mr. Haviv will hold one-on-one meetings with investors on September 13.

Evogene Ltd. (Nasdaq: EVGN) announced its Q2 2022 financial results, reporting revenues of $312,000, up from $135,000 in Q2 2021, attributed to the sales of Lavie Bio's Thrivus and Canonic products. Key developments include ICL's $10 million investment in Lavie Bio and the initiation of Biomica's Phase I clinical trial for its immuno-oncology drug candidate, BMC128. The company's net loss increased to $9.8 million from $6.9 million year-over-year, primarily due to financing expenses. Evogene maintains a solid cash position of approximately $35.3 million.

On August 25, 2022, Evogene Ltd. (Nasdaq: EVGN) announced it has regained compliance with Nasdaq Listing Rule 5450(a)(1), which mandates a minimum bid price of $1.00 per share. This decision followed a period of ten consecutive business days where the company’s ordinary shares closed at or above the required bid price. With this compliance, the previous bid price deficiency has been resolved, allowing Evogene to continue its operations without the risk of delisting from Nasdaq.